
==== Front
Adv TherAdv TherAdvances in Therapy0741-238X1865-8652Springer Healthcare Cheshire 2855063853910.1007/s12325-017-0539-2ErratumErratum to: Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index http://orcid.org/0000-0003-4275-468XOhki Takamasa lily.rover220@gmail.com 1Kondo Mayuko 1Karasawa Yuki 1Kawamura Satoshi 1Maeshima Shuuya 1Kojima Kentaro 1Seki Michiharu 1Toda Nobuo 1Shioda Yoshinobu 2Tagawa Kazumi 11 Department of Gastroenterology, Mitsui 20 Memorial Hospital, Tokyo, Japan 2 Department of Surgery, Shioda Hospital, Katsuura City, Japan 26 5 2017 26 5 2017 2017 34 7 1773 1774 © The Author(s) 2017issue-copyright-statement© Springer Healthcare Ltd. 2017
==== Body
Erratum to: Adv Ther DOI 10.1007/s12325-017-0524-9
The authors of the above mentioned paper would like to make the following amendment to the author affiliations.

Kazumi Tagawa’s affiliation currently reads “Department of Surgery, Shioda Hospital, Katsuura City, Japan”. The affiliation should read “Department of Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan”.

Finally, the authors would like to make the following amendments to Fig. 2. The x-axis labels for both Fig. 2a and Fig. 2b currently read "Time from TACE refractory (years)". The labels should read "Time (years)". The corrected Fig. 2 is provided here.Fig. 2 Cumulative survival rates for a SOR vs. CON and b mSOR vs. mCON. CON transcatheter arterial chemoembolization, mCON matched transcatheter arterial chemoembolization, mSOR matched sorafenib, SOR sorafenib




The online version of the original article can be found under doi:10.1007/s12325-017-0524-9.

Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

